Rapport Therapeutics Announces New Data And Post Hoc Analysis On Clinical And Patient Reported Benefits Of RAP-219 In Drug-Resistant FOS, Alongside Topline Efficacy And Safety Data From Phase 2a FOS Trial

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients' disease severity 

RAP-219 demonstrated meaningful improvements in patient-reported seizure severity among those with moderate or greater baseline impairment

BOSTON and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (NASDAQ:RAPP) (Rapport or the Company), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced new data and post hoc analysis on clinical and patient reported benefits of RAP-219 in drug-resistant focal onset seizures (FOS), alongside topline efficacy and safety data from its recently reported Phase 2a FOS trial. The results were presented at the 2025 American Epilepsy Society (AES) Annual Meeting and include RAP-219's early treatment effects and consistent median efficacy data across the full treatment period, its performance across varying levels of baseline disease severity, and its impact on seizure severity.